2022
DOI: 10.3947/ic.2022.0098
|View full text |Cite
|
Sign up to set email alerts
|

Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand

Abstract: Background In Thailand, active antibiotics against Gram-negative bacteria are limited. The re-emergence of intravenous (IV) fosfomycin is an alternative. IV fosfomycin has broad-spectrum activity, relative safety, and availability. The limitations of the clinical use of IV fosfomycin include the lack of susceptibility reports and unclear dosing. Therefore, this study was designed to examine the prescription pattern of IV fosfomycin in Chonburi Hospital, a provincial hospital in Thailand. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 32 publications
1
2
0
Order By: Relevance
“…In agreement with Putensen et al [14], also in our study, fosfomycin was not used as a therapeutic alternative in the perspective of a carbapenem-sparing regimen [28,29] but as a valid weapon of association with them especially in pneumonia (hospital-acquired and community-acquired pneumonia) and bacteremia/sepsis. Our use of the association of fosfomycin and colistin reported a clinical cure rate of 51.3%, similar to that described in other studies [26,[30][31][32]. These studies and other studies in the literature analyzing combination therapy with ceftazidime/avibactam are described in Table 5.…”
Section: Discussionsupporting
confidence: 85%
“…In agreement with Putensen et al [14], also in our study, fosfomycin was not used as a therapeutic alternative in the perspective of a carbapenem-sparing regimen [28,29] but as a valid weapon of association with them especially in pneumonia (hospital-acquired and community-acquired pneumonia) and bacteremia/sepsis. Our use of the association of fosfomycin and colistin reported a clinical cure rate of 51.3%, similar to that described in other studies [26,[30][31][32]. These studies and other studies in the literature analyzing combination therapy with ceftazidime/avibactam are described in Table 5.…”
Section: Discussionsupporting
confidence: 85%
“…Nonetheless, the predominant trend observed was the utilization of fosfomycin in combination with aminoglycosides. In Thailand, IV fosfomycin is commonly prescribed as part of combination therapy for resistant Gram‐negative bacteria, including CRE infections 29 , 31 and high‐dose IV fosfomycin (16–24 g/day) has been recommended for CRE infections based on MIC data. 29 , 30 , 32 , 33 , 34 However, it is primarily used for respiratory and urinary tract infections, with only 9.4% of its use targeting bloodstream infections.…”
Section: Discussionmentioning
confidence: 99%
“…However, it is the best way to deliver a dose rapidly and accurately, as the drug enters directly into systemic circulation without the delay associated to absorption processes, achieving its therapeutic efect faster than by any other route. Also, this route presents a bioavailability of 100%, since the pharmaceutical active ingredient usually reaches the site of action without sufering alterations due to presystemic efects [16][17][18][19]. Tough this route is very efcient, it needs the application of the right dose of the drug due to right prescription, for low or high dose of the drug may lead to many consequences such as antibiotic resistance, low efcacy of the drug, long stay in the hospital, and long treatment leading to high cost and possible high mortality rate [20][21][22].…”
Section: Discussionmentioning
confidence: 99%